These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 17119488

  • 1. [Evidence data and importance of public health of the new antipsychotics].
    Launois R.
    Encephale; 2006 Oct; 32(5 Pt 3):S861-5. PubMed ID: 17119488
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Clinical, functional, and economic ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia.
    Ascher-Svanum H, Nyhuis AW, Faries DE, Kinon BJ, Baker RW, Shekhar A.
    Schizophr Bull; 2008 Nov; 34(6):1163-71. PubMed ID: 18156640
    [Abstract] [Full Text] [Related]

  • 5. Clinical and economic ramifications of switching antipsychotics in the treatment of schizophrenia.
    Faries DE, Ascher-Svanum H, Nyhuis AW, Kinon BJ.
    BMC Psychiatry; 2009 Sep 02; 9():54. PubMed ID: 19725969
    [Abstract] [Full Text] [Related]

  • 6. A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in taiwan.
    Gau SS, Chung CH, Gau CS.
    J Clin Psychopharmacol; 2008 Jun 02; 28(3):271-8. PubMed ID: 18480683
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil.
    Barbosa WB, Costa JO, de Lemos LLP, Gomes RM, de Oliveira HN, Ruas CM, Acurcio FA, Barbui C, Bennie M, Godman B, Guerra AA.
    Appl Health Econ Health Policy; 2018 Oct 02; 16(5):697-709. PubMed ID: 30051254
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Is a guideline based treatment cost-effective for a middle income country? Results from a study with Mexican adolescents.
    Ayala L, Sauer T, Ulloa RE.
    Schizophr Res; 2018 Feb 02; 192():485-486. PubMed ID: 28601501
    [No Abstract] [Full Text] [Related]

  • 11. Length of stay and antipsychotic treatment costs of patients with acute psychosis admitted to hospital in Spain. Description and associated factors. The Psychosp study.
    Peiró S, Gómez G, Navarro M, Guadarrama I, Rejas J, Psychosp Group.
    Soc Psychiatry Psychiatr Epidemiol; 2004 Jul 02; 39(7):507-13. PubMed ID: 15243687
    [Abstract] [Full Text] [Related]

  • 12. New vs. old antipsychotics: the Texas experience.
    Reid WH.
    J Clin Psychiatry; 1999 Jul 02; 60 Suppl 1():23-5; discussion 28-30. PubMed ID: 10037167
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of medical and economic benefits of antipsychotics in the treatment of schizophrenia in France].
    Druais S, Doutriaux A, Cognet M, Godet A, Lançon C, Levy P, Samalin L, Guillon P.
    Encephale; 2017 Aug 02; 43(4):311-320. PubMed ID: 27623123
    [Abstract] [Full Text] [Related]

  • 14. The costs of drugs for schizophrenia.
    Freedman R, Carpenter WT, Davis JM, Goldman HH, Tamminga CA, Thomas M.
    Am J Psychiatry; 2006 Dec 02; 163(12):2029-31. PubMed ID: 17151146
    [No Abstract] [Full Text] [Related]

  • 15. [Priority for atypical antipsychotics--comments on the article by Dose M. Priority for Atypicals? Current studies clarify some aspects. Psychiat Prax 2007; 34:46-49].
    Fritze J, Aldenhoff J, Bergmann F, Eckermann G, Maier W, Möller HJ, Gaebel W.
    Psychiatr Prax; 2008 Mar 02; 35(2):94-7; author reply 97-8. PubMed ID: 17987542
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Psychiatric hospital utilization in patients treated with clozapine for up to 4.5 years in a state mental health care system.
    Reid WH, Mason M.
    J Clin Psychiatry; 1998 Apr 02; 59(4):189-94. PubMed ID: 9590670
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Perspective and the measurement of costs and benefits for cost-effectiveness analysis in schizophrenia.
    Meltzer D.
    J Clin Psychiatry; 1999 Apr 02; 60 Suppl 3():32-5; discussion 36-7. PubMed ID: 10073375
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care.
    Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA.
    J Ment Health Policy Econ; 2008 Jun 02; 11(2):89-97. PubMed ID: 18509216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.